Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

By K. Hay, L. Hanafi, Daniel H. Li, J. Gust, W. Liles, M. Wurfel, José A. López, Junmei Chen, D. Chung, Susanna Harju-Baker and 5 more. Blood, 2017

1,008 citations recorded by the source corpus.

Subfields: Oncology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Engineering strategies to overcome the current roadblocks in CAR T cell therapy (2019, background): “Increased appreciation and understanding of these characteristic toxicities has led to improved clinical management, with the establishment of grading and treatment guidelines 2,60 , changes to the method of cell isolation during manufacturing 62 and altered dosing levels 3,62 .”
Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) (2018, background): “The angiopoietin (ANG)–TIE2 axis, which regulates the balance between endothelial activation and quiescence, has recently been shown to be altered in patients with grade ≥ 4 neurotoxicity and CRS (11, 19).”
Cytokine release syndrome (2018, background): “Of note, in patients with CRS the need for mechanical ventilation is oftentimes not due to respiratory distress but instead a consequence of the inability to protect the airway secondary to neurotoxicity [26].”